6505-- Denosumab Injections
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NAC PHARMACEUTICALS (36E797)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36E79726R0018
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
This presolicitation notice announces the Department of Veterans Affairs (VA) National Acquisition Center’s intent to issue a Request for Proposal (RFP 36E79726R0018) for the procurement of Denosumab Injection. The procurement is designed to secure a reliable, uninterrupted supply of Denosumab injections for a range of federal healthcare entities, including the VA (with coverage for Consolidated Mail Order Pharmacies and State Veterans Homes), the Department of Defense (DoD), the Bureau of Prisons (BOP), the Indian Health Service (IHS), and the Federal Health Care Center (FHCC).
The scope of this procurement encompasses two primary Denosumab injection strengths: 60MG and 120MG. The estimated annual requirements are 22,737 units of the 60MG injection and 5,472 units of the 120MG injection, with each unit corresponding to a single vial or syringe. The contract will be awarded to a single responsible offeror capable of ensuring continuous supply throughout the contract period, which consists of a base year plus four pre-priced one-year option periods. Distribution will occur through the VA’s and DoD’s respective Pharmaceutical Prime Vendor Programs.
Key requirements for offerors include the necessity to supply Denosumab under the exact name as it appears on the product label, with a unique National Drug Code (NDC) specific to the offeror. The successful contractor’s label and NDC must be the only identifiers on the product; relabeling over another manufacturer’s label is strictly prohibited. If an offeror markets both vial and syringe presentations for the same strength, both must be offered at the same price. Should an alternate presentation become available post-award, it will be added to the contract at the awarded price for that strength.
This procurement is unrestricted and will be conducted in accordance with FAR Part 12 (Commercial Items). The applicable NAICS code is 325412 (Pharmaceutical Preparation Manufacturing), and the Product Service Code is 6505. The solicitation will be issued electronically via SAM.gov, with no paper copies available. Interested parties are responsible for monitoring SAM.gov for updates, amendments, and additional documents.
Special considerations apply to “covered drugs” as defined by 38 U.S.C. § 8126. Offerors proposing such drugs must have established Federal Ceiling Prices (FCPs) through the VA’s Pharmacy Benefits Management and must have executed Master Agreements and Pharmaceutical Pricing Agreements (including the offered NDCs) on file with the VA National Acquisition Center. All proposed covered drug products must be listed on the offeror’s Federal Supply Schedule (FSS) contract or interim agreement with an established Permanent FCP by the solicitation’s closing date. Offers not meeting these criteria will not be considered.
For biosimilar products, only FDA-licensed biological products that meet the criteria in 42 U.S.C. § 262 and are listed as biosimilars to the innovator product in the FDA Purple Book will be considered.
The contracting entity for this procurement is NAC Pharmaceuticals (36E797), a federal office within the Department of Veterans Affairs. The primary point of contact is Ray Roldan, who can be reached at [email protected] or 708-786-4930.
The anticipated solicitation release date is on or about April 17, 2026, with a tentative closing date of May 5, 2026. All responsible sources may submit an offer for consideration if received by the deadline.
Contractors evaluating this opportunity should ensure they can meet the requirements for product labeling, NDC uniqueness, FSS contract status, and uninterrupted supply, as well as comply with all federal pricing and biosimilar regulations as applicable. This procurement represents a significant opportunity to supply Denosumab injections to a broad federal healthcare customer base under a multi-year contract structure.